Mutation of NRAS but not KRAS significantly reduces myeloma sensitivity to single-agent bortezomib therapy.
about
KRAS Genotype Correlates with Proteasome Inhibitor Ixazomib Activity in Preclinical In Vivo Models of Colon and Non-Small Cell Lung Cancer: Potential Role of Tumor Metabolism.Advances in understanding prognosis in myeloma.A phase I trial of single-agent reolysin in patients with relapsed multiple myelomaImplications of heterogeneity in multiple myeloma.Revealing the inherent heterogeneity of human malignancies by variant consensus strategies coupled with cancer clonal analysis.SNaPshot as a Valuable Option for the Identification of Mutations in Myeloma.Combination of a Selective HSP90α/β Inhibitor and a RAS-RAF-MEK-ERK Signaling Pathway Inhibitor Triggers Synergistic Cytotoxicity in Multiple Myeloma Cells.Simultaneous suppression of the MAP kinase and NF-κB pathways provides a robust therapeutic potential for thyroid cancerMolecular spectrum of BRAF, NRAS and KRAS gene mutations in plasma cell dyscrasias: implication for MEK-ERK pathway activation.Tight Junction Protein 1 Modulates Proteasome Capacity and Proteasome Inhibitor Sensitivity in Multiple Myeloma via EGFR/JAK1/STAT3 Signaling.Aberrantly expressed LGR4 empowers Wnt signaling in multiple myeloma by hijacking osteoblast-derived R-spondins.Recurrent mutations of MAPK pathway genes in multiple myeloma but not in amyloid light-chain amyloidosis.Recent advances and future directions in targeting the secretory apparatus in multiple myeloma.Molecular deregulation of signaling in lymphoid tumors.Utilizing next-generation sequencing in the management of multiple myeloma.IQGAP1 Scaffold-MAP Kinase Interactions Enhance Multiple Myeloma Clonogenic Growth and Self-Renewal.Signaling Pathways and Emerging Therapies in Multiple Myeloma.Clinical Grade "SNaPshot" Genetic Mutation Profiling in Multiple MyelomaThe tyrosine phosphatase SHP2 is required for cell transformation by the receptor tyrosine kinase mutants FIP1L1-PDGFRα and PDGFRα D842V.RPL5 on 1p22.1 is recurrently deleted in multiple myeloma and its expression is linked to bortezomib response.Molecular signaling in multiple myeloma: association of RAS/RAF mutations and MEK/ERK pathway activation.Rare SNPs in receptor tyrosine kinases are negative outcome predictors in multiple myeloma.Comparison of intramedullary myeloma and corresponding extramedullary soft tissue plasmacytomas using genetic mutational panel analyses.Gene Expression Profiles in Myeloma: Ready for the Real World?RAS mutation status and bortezomib therapy for relapsed multiple myeloma.IndividualizedPath: identifying genetic alterations contributing to the dysfunctional pathways in glioblastoma individuals.Insights on Genomic and Molecular Alterations in Multiple Myeloma and Their Incorporation towards Risk-Adapted Treatment Strategy: Concise Clinical Review.Identifying mutual exclusivity across cancer genomes: computational approaches to discover genetic interaction and reveal tumor vulnerability.Isolation of circulating plasma cells from blood of patients diagnosed with clonal plasma cell disorders using cell selection microfluidics.Bortezomib/bendamustine/dexamethasone induced good PR in refractory relapse post auto-SCT with constitutive RAS activation due to V600E BRAF mutation.Neurofibromatosis type I and multiple myeloma coexistence: A possible link?Frequent functional activation of RAS signalling not explained by RAS/RAF mutations in relapsed/refractory multiple myeloma
P2860
Q27853300-5B0572B4-D95F-41FA-A1A2-7BE43432B0EDQ30244061-EEEA09C8-3A68-46EB-9939-CBD3126C9B8BQ33418048-7DFBA16E-B2ED-43F5-AD57-1B0C8E7901E7Q33914824-4C2515EE-E7E1-48E7-A554-0E353577374DQ34607063-1C339AF9-B269-44D9-ADF1-7519CBE7A2D9Q35797736-36ED3A5B-8787-44AE-A428-21D9C42B484BQ35859205-B323487C-1F9A-4F58-B2E9-CC9F3C84F336Q36012586-F4D2407A-49FA-4AD8-881C-4F0F5A18CA26Q36414422-5E50BE65-C332-4C01-942C-6BD900F773D8Q37171812-09E2FD07-93D5-4EC7-9C77-0BEB2DCD8DF0Q37589988-C2E4F38C-0B05-4262-967B-7C6531A7E99BQ37708798-AE6DFB56-4008-45F0-A43B-1967F537C7A6Q38258197-E6E655B3-5C35-48D3-842C-9410B624F5E2Q38424403-8BF520D9-CCC2-4AA3-81B1-DAE93D84AC7BQ38681814-6617B92A-23D9-44FB-9D84-5BE4AD7B289DQ38733973-6004B122-A0F6-4C6B-B667-BADF2A0C82D0Q38753307-E926D21F-D5F1-481B-B77D-85AA96F3B5DFQ38857256-784393D6-7896-43D6-A769-F3032088B79FQ39016533-D9028DCE-6F1E-48F5-879A-87917A92B54AQ39137868-310D8B5D-1916-4018-AFD7-D468629B0865Q41098492-96DAD84D-4398-4A81-AB81-0E0063715300Q41768870-28D1C7AF-B5AC-4CAF-8461-8C21B7D10772Q42577135-A1D11E6A-B5AD-44E7-B5FF-E0A335D5A992Q43847809-A9C93BE5-A35D-4A5C-B0FC-0436528CBF4BQ45066307-DB4E05CD-440A-44CA-919F-378867B61C67Q45794856-CE62AF56-8F7F-477D-87EC-BB056DB3F373Q47095937-D17F468A-4C73-43DF-838E-6D64A7C47BA1Q47664459-FFEA1AAA-E4B1-4879-ACD5-BAA5D868B1EFQ48160190-EEBE61A3-315E-429E-9CA9-44A70EB0320FQ54329197-910C9DCF-5A64-43F3-ACFD-769B0BE05AE2Q54940448-ABB7080F-9B54-4F6A-A67F-CE110C7D084BQ58756391-E62F0522-0810-4CF2-AE3C-F8858F2EC43A
P2860
Mutation of NRAS but not KRAS significantly reduces myeloma sensitivity to single-agent bortezomib therapy.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Mutation of NRAS but not KRAS ...... ngle-agent bortezomib therapy.
@en
type
label
Mutation of NRAS but not KRAS ...... ngle-agent bortezomib therapy.
@en
prefLabel
Mutation of NRAS but not KRAS ...... ngle-agent bortezomib therapy.
@en
P2093
P2860
P50
P1433
P1476
Mutation of NRAS but not KRAS ...... ngle-agent bortezomib therapy.
@en
P2093
Alessandra Di Bacco
Allison Berger
Andrew J Dorner
David I Lichter
Deborah Ricci
Dixie-Lee Esseltine
Edward A Stadtmauer
Erik Koenig
George Mulligan
P2860
P304
P356
10.1182/BLOOD-2013-05-504340
P407
P577
2013-12-11T00:00:00Z